Female infertility. Female infertility
Conditions
Interventions
Intervention 1: Control group:Eligible infertile women with polycystic ovary syndrome, referring to one of the private clinics in Rasht, who will be treated with letrozole in a dose of 5 mg/for 5 days
Sponsors
Rasht University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
No minimum to 35 Years
Inclusion criteria
Inclusion criteria: All infertile women with polycystic ovary syndrome resistant to letrozole primary treatment With full consent to participate in the study Under the age of 35 There is an indication for the use of oral medication (not received 6 cycles of ovulation induction medication)
Exclusion criteria
Exclusion criteria: Obstruction of the fallopian tubes Absence of a healthy uterine cavity Ovarian cysts Metabolic diseases and any disease that has a negative effect on ovulation Chronic heart, liver and kidney diseases Abnormal sperm analysis Using other ovulation induction drugs at the same time
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The size of mature follicle equal to 17 mm in sonographic evaluation. Timepoint: On day 22-23 of the cycle. Method of measurement: By transvaginal ultrasound. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biochemical pregnancy rate. Timepoint: 2-3 weeks after seeing the mature follicle. Method of measurement: through laboratory measurement (BhCG level).;Clinical pregnancy. Timepoint: in 6-7 weeks of pregnancy. Method of measurement: Observation of fetal heartbeat in sonographic evaluation.;Early pregnancy failure(Ioss of pregnancy products before week12). Timepoint: Before week 12. Method of measurement: By transvaginal ultrasound.;Multiple pregnancy (seeing two or more gestational sacs and fetal heart rate in them. Timepoint: In 6-7 weeks of pregnancy. Method of measurement: By transvaginal ultrasound.;Ectopic pregnancy (implantation somewhere other than inside the uterine cavity). Timepoint: In week 5-7. Method of measurement: By transvaginal ultrasound.;Side effects of letrozole include: bone pain, fatigue, nausea, night sweats, hot flashes, headache and dizziness. Timepoint: At any time during the study process. Method of measurement: It is checked by a questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Ziba Zahiri Sorouri
Rasht University of Medical Sciences
Outcome results
None listed